Xenogeneic-derived biomaterials are among the most routinely employed bone substitutes for immediate grafting of extraction sites as a modality of alveolar ridge preservation (ARP). The deproteinized bovine bone material is an example of which is widely used and documented by many around the world. The present pilot clinical trial aimed at evaluating and comparing the clinical and morphological alterations of extraction sites after ARP, using two commercially available differently processed bovine bone grafts. Twenty adjacent extraction sites in ten patients were included. All sites received the exact same ARP therapy, except for the specific type of bovine bone graft which was randomly assigned between two adjacent extraction sockets in 10 patients (group A receiving Bio-Oss particles, and group B receiving Cerabone particles). The healing at all sites was monitored throughout the process at equal intervals, at time of surgery, 1 month, 2 months, 3 months and 4 months post operatively. All the augmented extraction sites successfully received implant therapy regardless of the type of bone graft material that was used for the ARP. And 6 weeks later, second stage/uncovery procedures were performed without complications. Inter-group comparisons of Crestal gingiva healing process (CGHP), Mean Transversal crestal ridge resorption (MTRR), and the Mean implant primary stability (MIPS) were in favor of site that were allocated to group A (treatment with Bio-Oss particles).